A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease

Hum Vaccin Immunother. 2016;12(2):519-27. doi: 10.1080/21645515.2015.1078045.


Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal with no approved vaccine available. In the present study, the attenuated poxvirus vector, Modified Vaccinia virus Ankara, was used to develop a recombinant candidate vaccine expressing the CCHF virus nucleoprotein. Cellular and humoral immunogenicity was confirmed in 2 mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. Despite the immune responses generated post-immunisation, the vaccine failed to protect animals from lethal disease in a challenge model.

Keywords: Crimean-Congo hemorrhagic fever, nucleoprotein, protection, vaccine.

MeSH terms

  • Animals
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Cell Line
  • Chick Embryo
  • Chlorocebus aethiops
  • Cricetinae
  • Hemorrhagic Fever Virus, Crimean-Congo / immunology*
  • Hemorrhagic Fever, Crimean / immunology
  • Hemorrhagic Fever, Crimean / prevention & control*
  • Humans
  • Immunization
  • Immunogenicity, Vaccine / immunology*
  • Mice
  • Mice, Knockout
  • Nucleoproteins / immunology*
  • Receptor, Interferon alpha-beta / genetics
  • Vaccines, Synthetic / immunology*
  • Vero Cells
  • Viral Load / immunology
  • Viral Proteins / immunology*
  • Viral Vaccines / immunology*


  • Antibodies, Viral
  • Nucleoproteins
  • Vaccines, Synthetic
  • Viral Proteins
  • Viral Vaccines
  • Receptor, Interferon alpha-beta